Download PDF
Int J Angiol 2020; 29(02): 072-080
DOI: 10.1055/s-0039-3400541
Invited Articles
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

AGE–RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment

Kailash Prasad
1   Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatchewan, Saskatoon, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2019 (online)

   Permissions and Reprints

Abstract

Atrial fibrillation (AF) is the most common of cardiac arrhythmias. Mechanisms such as atrial structural remodeling and electrical remodeling have been implicated in the pathogenesis of AF. The data to date suggest that advanced glycation end products (AGEs) and its cell receptor RAGE (receptor for AGE) and soluble receptor (sRAGE) are involved in the pathogenesis of AF. This review focuses on the role of AGE–RAGE axis in the pathogenesis of AF. Interaction of AGE with RAGE generates reactive oxygen species, cytokines, and vascular cell adhesion molecules. sRAGE is a cytoprotective agent. The data show that serum levels of AGE and sRAGE, and expression of RAGE, are elevated in AF patients. Elevated levels of sRAGE did not protect the development of AF. This might be due to greater elevation of AGE than sRAGE. Measurement of AGE–RAGE stress (AGE/sRAGE) would be appropriate as compared with measurement of AGE or RAGE or sRAGE alone in AF patients. AGE and its interaction with RAGE can induce AF through alteration in cellular protein and extracellular matrix. AGE and its interaction with RAGE induce atrial structural and electrical remodeling. The treatment strategy should be directed toward reduction in AGE levels, suppression of RAGE expression, blocking of binding of AGE to RAGE, and elevation of sRAGE and antioxidants. In conclusion, AGE–RAGE axis is involved in the development of AF through atrial structural and electrical remodeling. The treatment modalities for AF should include lowering of AGE, suppression of RAGE, elevation of sRAGE, and use of antioxidants.

Keywords

advanced glycation end products - cell receptor for age - soluble RAGE - atrial fibrillation - atrial structural remodeling - atrial electrical remodeling - treatment modalities

Disclosure

None.


 

  • References

  • 1 Begieneman MP, Rijvers L, Kubat B. , et al. Atrial fibrillation coincides with the advanced glycation end product N(ε)-(carboxymethyl)lysine in the atrium. Am J Pathol 2015; 185 (08) 2096-2104
    CrossrefPubMedGoogle Scholar
  • 2 Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51 (08) 802-809
    CrossrefPubMedGoogle Scholar
  • 3 Boldt A, Wetzel U, Lauschke J. , et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90 (04) 400-405
    CrossrefPubMedGoogle Scholar
  • 4 Geuzebroek GS, van Amersfoorth SC, Hoogendijk MG. , et al. Increased amount of atrial fibrosis in patients with atrial fibrillation secondary to mitral valve disease. J Thorac Cardiovasc Surg 2012; 144 (02) 327-333
    CrossrefPubMedGoogle Scholar
  • 5 McNair ED, Wells CR, Qureshi AM. , et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 2009; 18 (04) 187-192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Caspar-Bell G, Dhar I, Prasad K. Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism. Mol Cell Biochem 2016; 414 (1-2): 171-178
    CrossrefPubMedGoogle Scholar
  • 7 Prasad K. AGE-RAGE stress in the pathophysiology of pulmonary hypertension and its treatment. Int J Angiol 2019; 28 (02) 71-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L. , et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol 2012; 157 (03) 397-402
    CrossrefPubMedGoogle Scholar
  • 9 Piccini JP, Hammill BG, Sinner MF. , et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 2012; 5 (01) 85-93
    CrossrefPubMedGoogle Scholar
  • 10 Lloyd-Jones DM, Wang TJ, Leip EP. , et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110 (09) 1042-1046
    CrossrefPubMedGoogle Scholar
  • 11 Chugh SS, Havmoeller R, Narayanan K. , et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129 (08) 837-847
    CrossrefPubMedGoogle Scholar
  • 12 Go AS, Hylek EM, Phillips KA. , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18) 2370-2375
    CrossrefPubMedGoogle Scholar
  • 13 Miyasaka Y, Barnes ME, Gersh BJ. , et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114 (02) 119-125
    CrossrefPubMedGoogle Scholar
  • 14 Allessie MA, Boyden PA, Camm AJ. , et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103 (05) 769-777
    CrossrefPubMedGoogle Scholar
  • 15 Nattel S. From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. Can J Cardiol 2011; 27 (01) 19-26
    CrossrefPubMedGoogle Scholar
  • 16 Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001; 142 (05) 838-842
    CrossrefPubMedGoogle Scholar
  • 17 Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: causes of ‘not-so-lone atrial fibrillation’. Europace 2008; 10 (06) 668-673
    CrossrefPubMedGoogle Scholar
  • 18 Atrial fibrillation: symptoms and causes. Available at: https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/diagnosis-treatment/drc-20350630 . Accessed October 15, 2019
    PubMed
  • 19 Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306 (17) 1018-1022
    CrossrefPubMedGoogle Scholar
  • 20 Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82 (8A): 2N-9N
    CrossrefPubMedGoogle Scholar
  • 21 Mitchell GF, Vasan RS, Keyes MJ. , et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007; 297 (07) 709-715
    CrossrefPubMedGoogle Scholar
  • 22 Mahida S, Lubitz SA, Rienstra M, Milan DJ, Ellinor PT. Monogenic atrial fibrillation as pathophysiological paradigms. Cardiovasc Res 2011; 89 (04) 692-700
    CrossrefPubMedGoogle Scholar
  • 23 Healey JS, Connolly SJ, Gold MR. , et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366 (02) 120-129
    CrossrefPubMedGoogle Scholar
  • 24 Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008; 156 (01) 57-64
    CrossrefPubMedGoogle Scholar
  • 25 Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91 (01) 265-325
    CrossrefPubMedGoogle Scholar
  • 26 Wakilli R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. Clin Invest 2011; 121: 2955-2968
    CrossrefPubMedGoogle Scholar
  • 27 Katz AM. Proliferative signaling and disease progression in heart failure. Circ J 2002; 66 (03) 225-231
    CrossrefPubMedGoogle Scholar
  • 28 Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996; 107 (03) 404-411
    CrossrefPubMedGoogle Scholar
  • 29 Twigg SM, Cao Z, MCLennan SV. , et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143 (12) 4907-4915
    CrossrefPubMedGoogle Scholar
  • 30 Mazurek T, Kiliszek M, Kobylecka M. , et al. Relation of proinflammatory activity of epicardial adipose tissue to the occurrence of atrial fibrillation. Am J Cardiol 2014; 113 (09) 1505-1508
    CrossrefPubMedGoogle Scholar
  • 31 Burstein B, Comtois P, Michael G. , et al. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 2009; 105 (12) 1213-1222
    CrossrefPubMedGoogle Scholar
  • 32 Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 2011; 89 (04) 744-753
    CrossrefPubMedGoogle Scholar
  • 33 Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1 (01) 62-73
    CrossrefPubMedGoogle Scholar
  • 34 Li D, Shinagawa K, Pang L. , et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104 (21) 2608-2614
    CrossrefPubMedGoogle Scholar
  • 35 Shiroshita-Takeshita A, Brundel BJ, Burstein B. , et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007; 74 (01) 75-84
    CrossrefPubMedGoogle Scholar
  • 36 Abed HS, Wittert GA, Leong DP. , et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 310 (19) 2050-2060
    CrossrefPubMedGoogle Scholar
  • 37 John B, Stiles MK, Kuklik P. , et al. Reverse remodeling of the atria after treatment of chronic stretch in humans: implications for the atrial fibrillation substrate. J Am Coll Cardiol 2010; 55 (12) 1217-1226
    CrossrefPubMedGoogle Scholar
  • 38 Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98 (05) 476-484
    CrossrefPubMedGoogle Scholar
  • 39 Haïssaguerre M, Jaïs P, Shah DC. , et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339 (10) 659-666
    CrossrefPubMedGoogle Scholar
  • 40 Gelband H, Bush HL, Rosen MR, Myerburg RJ, Hoffman BF. Electrophysiologic properties of isolated preparations of human atrial myocardium. Circ Res 1972; 30 (03) 293-300
    CrossrefPubMedGoogle Scholar
  • 41 Prasad K. Transmembrane potential and force of contraction of the normal and potassium-deficient human atrial tissue in vitro. Can J Physiol Pharmacol 1969; 47 (12) 1015-1024
    CrossrefPubMedGoogle Scholar
  • 42 Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008; 5 (05) 704-709
    CrossrefPubMedGoogle Scholar
  • 43 Iwasaki Y-K, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation 2011; 124 (20) 2264-2274
    CrossrefPubMedGoogle Scholar
  • 44 Dobrev D, Voigt N, Wehrens XH. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res 2011; 89 (04) 734-743
    CrossrefPubMedGoogle Scholar
  • 45 Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415 (6868): 219-226
    PubMedGoogle Scholar
  • 46 Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
    PubMedGoogle Scholar
  • 47 Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003; 25 (3-4): 275-281
    CrossrefPubMedGoogle Scholar
  • 48 Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009; 116 (08) 621-637
    CrossrefPubMedGoogle Scholar
  • 49 Yonekura H, Yamamoto Y, Sakurai S. , et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3): 1097-1109
    CrossrefPubMedGoogle Scholar
  • 50 Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology 2012; 58 (03) 227-237
    CrossrefPubMedGoogle Scholar
  • 51 Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280 (05) E685-E694
    CrossrefPubMedGoogle Scholar
  • 52 Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72 (11) 1493-1505
    CrossrefPubMedGoogle Scholar
  • 53 Reznikov LL, Waksman J, Azam T. , et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004; 61 (05) 324-336
    CrossrefPubMedGoogle Scholar
  • 54 Stassen M, Müller C, Arnold M. , et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-κ B is decisively involved in the expression of IL-9. J Immunol 2001; 166 (07) 4391-4398
    CrossrefPubMedGoogle Scholar
  • 55 Mohammed AM, Syeda K, Hadden T, Kowluru A. Upregulation of phagocyte-like NADPH oxidase by cytokines in pancreatic beta-cells: attenuation of oxidative and nitrosative stress by 2-bromopalmitate. Biochem Pharmacol 2013; 85 (01) 109-114
    CrossrefPubMedGoogle Scholar
  • 56 Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 2007; 85 (04) 462-472
    CrossrefPubMedGoogle Scholar
  • 57 Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011; 120 (02) 81-89
    CrossrefPubMedGoogle Scholar
  • 58 Koyama H, Shoji T, Yokoyama H. , et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2587-2593
    CrossrefPubMedGoogle Scholar
  • 59 Prasad K, Dhar I, Zhou Q, Elmoselhi H, Shoker M, Shoker A. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem 2016; 423 (1-2): 105-114
    CrossrefPubMedGoogle Scholar
  • 60 Prasad K, Tiwari S. Therapeutic interventions for advanced glycation-end products and its receptor- mediated cardiovascular disease. Curr Pharm Des 2017; 23 (06) 937-943
    CrossrefPubMedGoogle Scholar
  • 61 Wendt T, Harja E, Bucciarelli L. , et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185 (01) 70-77
    CrossrefPubMedGoogle Scholar
  • 62 Kuryata O, Muhammad M, Mytrokhina O. Levels of glycation end products and galacti-3 in patients with chronic heart failure and atrial fibrillation in dependence on the age and renal function. EUREKA: Health Sciences 2018. Available at: http://eu-jr.eu/health/article/view/542 . Accessed October 25, 2019
    PubMedGoogle Scholar
  • 63 Kato T, Yamashita T, Sekiguchi A. , et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008; 19 (04) 415-420
    PubMedGoogle Scholar
  • 64 Yan X, Shen Y, Lu L, Sano M, Fukuda K, Shen W. Decreased endogenous secretory RAGE and increased hsCRP levels in serum are associated with atrial fibrillation in patients undergoing coronary angiography. Int J Cardiol 2013; 166 (01) 242-245
    CrossrefPubMedGoogle Scholar
  • 65 Lancefield TF, Patel SK, Freeman M. , et al. The receptor for advanced glycation end products (RAGE) is associated with persistent atrial fibrillation. PLoS One 2016; 11 (09) e0161715
    CrossrefPubMedGoogle Scholar
  • 66 Zhao D, Wang Y, Xu Y. Decreased serum endogenous secretory receptor for advanced glycation endproducts and increased cleaved receptor for advanced glycation endproducts levels in patients with atrial fibrillation. Int J Cardiol 2012; 158 (03) 471-472
    CrossrefPubMedGoogle Scholar
  • 67 Al Rifai M, Schneider ALC, Alonso A. , et al. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications 2015; 29 (02) 180-185
    CrossrefPubMedGoogle Scholar
  • 68 Yang PS, Kim TH, Uhm JS. , et al. High plasma level of soluble RAGE is independently associated with a low recurrence of atrial fibrillation after catheter ablation in diabetic patient. Europace 2016; 18 (11) 1711-1718
    CrossrefPubMedGoogle Scholar
  • 69 Schmidt AM, Hori O, Chen JX. , et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96 (03) 1395-1403
    CrossrefPubMedGoogle Scholar
  • 70 Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988; 203 (02) 495-505
    CrossrefPubMedGoogle Scholar
  • 71 van Heerebeek L, Hamdani N, Handoko ML. , et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117 (01) 43-51
    CrossrefPubMedGoogle Scholar
  • 72 Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8 (03) 171-179
    CrossrefPubMedGoogle Scholar
  • 73 Park IS, Kiyomoto H, Abboud SL, Abboud HE. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997; 46 (03) 473-480
    CrossrefPubMedGoogle Scholar
  • 74 Riser BL, Denichilo M, Cortes P. , et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11 (01) 25-38
    CrossrefPubMedGoogle Scholar
  • 75 Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 2004; 165 (06) 2033-2043
    CrossrefPubMedGoogle Scholar
  • 76 Li YY, Feng YQ, Kadokami T. , et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 2000; 97 (23) 12746-12751
    CrossrefPubMedGoogle Scholar
  • 77 Park S-K, Kim J, Seomun Y. , et al. Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 2001; 284 (04) 966-971
    CrossrefPubMedGoogle Scholar
  • 78 Richter K, Kietzmann T. Reactive oxygen species and fibrosis: further evidence of a significant liaison. Cell Tissue Res 2016; 365 (03) 591-605
    CrossrefPubMedGoogle Scholar
  • 79 Hecker L, Vittal R, Jones T. , et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15 (09) 1077-1081
    CrossrefPubMedGoogle Scholar
  • 80 Liew R, Khairunnisa K, Gu Y. , et al. Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J 2013; 77 (05) 1171-1179
    CrossrefPubMedGoogle Scholar
  • 81 Willeit K, Pechlaner R, Willeit P. , et al. Association between vascular cell adhesion molecule 1 and atrial fibrillation. JAMA Cardiol 2017; 2 (05) 516-523
    CrossrefPubMedGoogle Scholar
  • 82 Verdejo H, Roldan J, Garcia L. , et al. Systemic vascular cell adhesion molecule-1 predicts the occurrence of post-operative atrial fibrillation. Int J Cardiol 2011; 150 (03) 270-276
    CrossrefPubMedGoogle Scholar
  • 83 Ono N, Hayashi H, Kawase A. , et al. Spontaneous atrial fibrillation initiated by triggered activity near the pulmonary veins in aged rats subjected to glycolytic inhibition. Am J Physiol Heart Circ Physiol 2007; 292 (01) H639-H648
    CrossrefPubMedGoogle Scholar
  • 84 Cortassa S, Aon MA, Marbán E, Winslow RL, O'Rourke B. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J 2003; 84 (04) 2734-2755
    CrossrefPubMedGoogle Scholar
  • 85 Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100 (01) 87-95
    CrossrefPubMedGoogle Scholar
  • 86 Derakhchan K, Li D, Courtemanche M. , et al. Method for simultaneous epicardial and endocardial mapping of in vivo canine heart: application to atrial conduction properties and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001; 12 (05) 548-555
    PubMedGoogle Scholar
  • 87 Thomas GP, Sims SM, Cook MA, Karmazyn M. Hydrogen peroxide-induced stimulation of L-type calcium current in guinea pig ventricular myocytes and its inhibition by adenosine A1 receptor activation. J Pharmacol Exp Ther 1998; 286 (03) 1208-1214
    PubMedGoogle Scholar
  • 88 Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 2006; 318 (01) 214-222
    CrossrefPubMedGoogle Scholar
  • 89 Murrell GA, Francis MJ, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990; 265 (03) 659-665
    CrossrefPubMedGoogle Scholar
  • 90 Lee SH, Chen YC, Chen YJ. , et al. Tumor necrosis factor-α alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci 2007; 80 (19) 1806-1815
    CrossrefPubMedGoogle Scholar
  • 91 Saba S, Janczewski AM, Baker LC. , et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am J Physiol Heart Circ Physiol 2005; 289 (04) H1456-H1467
    CrossrefPubMedGoogle Scholar
  • 92 Musa H, Kaur K, O'Connell R. , et al. Inhibition of platelet-derived growth factor-AB signaling prevents electromechanical remodeling of adult atrial myocytes that contact myofibroblasts. Heart Rhythm 2013; 10 (07) 1044-1051
    CrossrefPubMedGoogle Scholar
  • 93 Ishii Y, Schuessler RB, Gaynor SL. , et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation 2005; 111 (22) 2881-2888
    CrossrefPubMedGoogle Scholar
  • 94 Choi EK, Chang PC, Lee YS. , et al. Triggered firing and atrial fibrillation in transgenic mice with selective atrial fibrosis induced by overexpression of TGF-β1. Circ J 2012; 76 (06) 1354-1362
    CrossrefPubMedGoogle Scholar
  • 95 Prasad K. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease. Mol Cell Biochem 2019; 459 (1-2): 95-112
    CrossrefPubMedGoogle Scholar
  • 96 Prasad K, Mishra M. Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension. Int J Angiol 2017; 26 (01) 1-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 97 TransTech Pharma LLC; 2014. Available at: http://bciq,biocentury.com/companies/transtech.pharma_inc . Accessed March 10, 2014
    PubMed
  • 98 Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011; 25 (03) 206-212
    CrossrefPubMedGoogle Scholar
  • 99 Park L, Raman KG, Lee KJ. , et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4 (09) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 100 Sakaguchi T, Yan SF, Yan SD. , et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111 (07) 959-972
    CrossrefPubMedGoogle Scholar
  • 101 Wautier JL, Zoukourian C, Chappey O. , et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97 (01) 238-243
    CrossrefPubMedGoogle Scholar
  • 102 Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010; 79 (10) 1379-1386
    CrossrefPubMedGoogle Scholar
  • 103 Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011; 31 (02) 91-97
    CrossrefPubMedGoogle Scholar
  • 104 Youn J-Y, Zhang J, Zhang Y. , et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol 2013; 62: 72-79
    CrossrefPubMedGoogle Scholar
  • 105 Carnes CA, Chung MK, Nakayama T. , et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89 (06) E32-E38
    PubMedGoogle Scholar
  • 106 Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110 (16) 2313-2319
    CrossrefPubMedGoogle Scholar
  • 107 Khabchabov R, Khabchabov RG, Makhmudova ER. Antiarrhythmic effect of antioxidants in patients with atrial fibrillation. J Atr Fibrillation 2016; 8 (06) 1360
    PubMedGoogle Scholar
  • 108 Costanzo S, De Curtis A, di Niro V. , et al; Polyphemus Observational Study Investigators. Postoperative atrial fibrillation and total dietary antioxidant capacity in patients undergoing cardiac surgery: the Polyphemus Observational Study. J Thorac Cardiovasc Surg 2015; 149 (04) 1175-82.e1
    CrossrefPubMedGoogle Scholar
  • 109 Rodrigo R, Vinay J, Castillo R. , et al. Use of vitamins C and E as a prophylactic therapy to prevent postoperative atrial fibrillation. Int J Cardiol 2010; 138 (03) 221-228
    CrossrefPubMedGoogle Scholar
  • 110 Liu T, Li G. Antioxidant interventions as novel preventive strategies for postoperative atrial fibrillation. Int J Cardiol 2010; 145 (01) 140-142
    CrossrefPubMedGoogle Scholar
  • 111 Harling L, Rasoli S, Vecht JA, Ashrafian H, Kourliouros A, Athanasiou T. Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials. Heart 2011; 97 (20) 1636-1642
    PubMedGoogle Scholar
  • 112 Rasoli S, Kakouros N, Harling L. , et al. Antioxidant vitamins in the prevention of atrial fibrillation: what is the evidence?. Cardiol Res Pract 2011; 2011: 164078
    PubMedGoogle Scholar
  • 113 Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol 2014; 23 (01) 11-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 114 Tan KCB, Shiu SWM, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49 (11) 2756-2762
    CrossrefPubMedGoogle Scholar
  • 115 Prasad K, Mishra M. AGE-RAGE stress, stressors, and antistressors in health and disease. Int J Angiol 2018; 27 (01) 1-12
    Article in Thieme ConnectPubMedGoogle Scholar